Related Experiment Video
Updated: Aug 5, 2026
07:02
Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)
Published on: September 14, 2010
Immunostaining for CD31 and CD34 in Kaposi sarcoma
R Russell Jones1, G Orchard, B Zelger
1St John's Institute of Dermatology, St Thomas's Hospital, London.
Journal of Clinical Pathology
|November 1, 1995
Summary
Immunohistochemical markers CD34 and CD31 are superior to traditional markers for diagnosing Kaposi sarcoma. These endothelial cell markers aid in understanding the histogenesis of this complex tumor.
Area of Science:
- Oncology
- Immunohistochemistry
- Pathology
Background:
- Kaposi sarcoma is a complex tumor with debated histogenesis.
- Traditional endothelial cell markers like Ulex europaeus agglutinin 1 (UEA-1) and factor VIII related antigen have limitations in diagnosis.
Purpose of the Study:
- To evaluate antibodies against CD31 (JC70/A) and CD34 (QBEND/10, anti-HPCA-1) in Kaposi sarcoma.
- To assess their diagnostic utility in routine practice.
- To compare their efficacy with UEA-1 and factor VIII related antigen.
Main Methods:
- Retrospective analysis of 24 formalin-fixed, paraffin-embedded Kaposi sarcoma cases.
- Immunohistochemical staining using Streptavidin biotin technique for CD34 and CD31 antibodies.
- Comparison with UEA-1 and factor VIII related antigen using established methods.
Main Results:
- CD34 antibodies (QBEND/10, HPCA-1) showed universal labeling of Kaposi sarcoma lesions.
- CD31 (JC70/A) provided less consistent labeling of spindle cells.
- Both CD34 and CD31 demonstrated superior performance compared to UEA-1 and factor VIII related antigen.
Conclusions:
- Kaposi sarcoma is confirmed as a tumor of endothelial cell origin.
- CD34 and CD31 immunostaining aids in diagnosing Kaposi sarcoma in routinely processed tissues.
- These markers offer insights into the histogenesis of Kaposi sarcoma.
